Empagliflozin alleviates type 2 diabetic renal fibrosis by inhibiting SLC7A7-mediated ferroptosis
Abstract Background Diabetic Kidney Disease (DKD) represents the most prevalent secondary kidney condition that progresses to end-stage renal disease globally. Empagliflozin (EMPA) effectively reduce blood glucose levels to mitigate the impact of DKD. Methods Researchers extracted kidney tissues fro...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-025-01902-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|